The Influence of Fortified Pomegranate Juice (Punica Granatum) on Seasonal Influenza and Swine Flu Patients

The recruitment status of this study is unknown because the information has not been verified recently.
Verified September 2009 by Hillel Yaffe Medical Center.
Recruitment status was  Not yet recruiting
Sponsor:
Collaborator:
Gan-Shmuel Foods, Ltd.
Information provided by:
Hillel Yaffe Medical Center
ClinicalTrials.gov Identifier:
NCT00987012
First received: September 29, 2009
Last updated: NA
Last verified: September 2009
History: No changes posted
  Purpose

It has been shown in laboratory studies that pomegranate juice contains anti-viral action against influenza. The researchers wish to investigate the effect of pomegranate juice on patients suffering from influenza A (seasonal or swine flu).


Condition Intervention
Influenza A
Swine Flu
Dietary Supplement: Pomegranate juice
Dietary Supplement: Placebo drink

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: The Influence of Fortified Pomegranate Juice (Punica Granatum) on Seasonal Influenza and Swine Flu Patients - A Prospective Randomized Trial

Resource links provided by NLM:


Further study details as provided by Hillel Yaffe Medical Center:

Primary Outcome Measures:
  • Early relief of influenza symptoms [ Time Frame: Within one week ] [ Designated as safety issue: No ]

Estimated Enrollment: 200
Study Start Date: October 2009
Estimated Primary Completion Date: April 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Pomegranate juice Dietary Supplement: Pomegranate juice
Twice daily ingestion of pomegranate juice over 4-5 days
Placebo Comparator: Placebo drink Dietary Supplement: Placebo drink
Twice daily ingestion of placebo drink over 4-5 days

  Eligibility

Ages Eligible for Study:   12 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Individuals confirmed and suffering from Influenza A

Exclusion Criteria:

  • Individuals suffering from influenza included in the high risk group
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00987012

Locations
Israel
Hillel Yaffe Medical Center Not yet recruiting
Hadera, Israel, 38100
Contact: Gershon Keren, MD    972-4-6304218    gershonk@hy.health.gov.il   
Contact: Izhak Braverman, MD         
Sponsors and Collaborators
Hillel Yaffe Medical Center
Gan-Shmuel Foods, Ltd.
  More Information

No publications provided

Responsible Party: Dr. Gershon Keren, Hillel Yaffe Medical Center
ClinicalTrials.gov Identifier: NCT00987012     History of Changes
Other Study ID Numbers: 0044-09-HYMC
Study First Received: September 29, 2009
Last Updated: September 29, 2009
Health Authority: Israel: Ministry of Health

Additional relevant MeSH terms:
Influenza, Human
Orthomyxoviridae Infections
RNA Virus Infections
Virus Diseases
Respiratory Tract Infections
Respiratory Tract Diseases

ClinicalTrials.gov processed this record on July 24, 2014